HOUSE BILL No. 1203

DIGEST OF INTRODUCED BILL

Citations Affected: IC 35-31.5-2; IC 35-46-5-3.

Synopsis: Qualified egg banks. Amends, for purposes of the law regarding unlawful transfer of a human organism, the definition of "qualified third party" and changes the term to "qualified egg bank". Specifies qualifications for a physician overseeing medical services related to ovum cryopreservation. Specifies requirements that must be met by a fertility clinic or similar medical facility in order to be considered a qualified egg bank. Exempts from the criminal offense of unlawful transfer of a human organism the payment to or receipt by a qualified egg bank of an amount for: (1) the retrieval of a human ovum; (2) the cryopreservation of a human ovum; (3) the transportation of a human ovum; or (4) other aspects of specified treatments or procedures to enhance human reproductive capability.

Effective: July 1, 2018.

Eberhart

January 9, 2018, read first time and referred to Committee on Public Health.



Second Regular Session of the 120th General Assembly (2018)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or *this style type* reconciles conflicts between statutes enacted by the 2017 Regular Session of the General Assembly.

HOUSE BILL No. 1203

A BILL FOR AN ACT to amend the Indiana Code concerning criminal law and procedure.

Be it enacted by the General Assembly of the State of Indiana:

1	SECTION 1. IC 35-31.5-2-186.3 IS ADDED TO THE INDIANA
2	CODE AS A NEW SECTION TO READ AS FOLLOWS
3	[EFFECTIVE JULY 1, 2018]: Sec. 186.3. "Lethal fetal anomaly", for
4	purposes of IC 35-46-5-3, has the meaning set forth in
5	IC 35-46-5-3(a).
6	SECTION 2. IC 35-31.5-2-235.5 IS ADDED TO THE INDIANA
7	CODE AS A NEW SECTION TO READ AS FOLLOWS
8	[EFFECTIVE JULY 1, 2018]: Sec. 235.5. "Physician", for purposes
9	of IC 35-46-5-3, has the meaning set forth in IC 35-46-5-3(b).
0	SECTION 3. IC 35-31.5-2-264.8 IS ADDED TO THE INDIANA
1	CODE AS A NEW SECTION TO READ AS FOLLOWS
2	[EFFECTIVE JULY 1, 2018]: Sec. 264.8. "Qualified egg bank", for
3	purposes of IC 35-46-5-3, has the meaning set forth in
4	IC 35-46-5-3(c).
5	SECTION 4. IC 35-46-5-3, AS AMENDED BY P.L.213-2016,
6	SECTION 31, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
7	JULY 1, 2018]: Sec. 3. (a) As used in this section, "lethal fetal



1	anomaly" means a fetal condition diagnosed before birth that, if the
2	pregnancy results in a live birth, will with reasonable certainty result
3	in the death of the child not more than three (3) months after the child's
4	birth.
5	(b) As used in this section, "physician" means an individual
6	who:
7	(1) is licensed to practice medicine in:
8	(A) Indiana under IC 25-22.5; or
9	(B) another state in the United States in which the
10	individual is providing medical services;
11	(2) is board certified in obstetrics and gynecology; and
12	(3) oversees medical services related to ovum
13	cryopreservation.
14	(b) (c) As used in this section, "qualified third party" egg bank"
15	means:
16	(1) a fertility clinic or similar medical facility that:
17	(A) is located in the United States;
18	(1) (B) is accredited by an entity approved by:
19	(i) the medical licensing board, if the fertility clinic or
20	facility is located in Indiana; or
21	(ii) the authorizing state agency or licensing board in the
22	state in which the fertility clinic or facility is located;
23	(2) (C) is registered under 21 CFR 1271 with the United States
24	Food and Drug Administration; and
25	(3) (D) is owned by, employs, a contracts with, or is
26	affiliated with at least one (1) physician licensed under
27	IC 25-22.5 who performs medical services related to ovum
28	cryopreservation at the fertility clinic or facility; or
29	(A) is board certified in obstetrics and gynecology; and
30	(B) performs oocyte eryopreservation at the facility.
31	(2) an entity whose primary business purpose includes the
32	facilitation of in vitro fertilization using cryopreserved ova
33	and that is registered under 21 CFR 1271 with the United
34	States Food and Drug Administration.
35	(c) (d) Except as provided in subsection (e), a person who
36	knowingly or intentionally purchases or sells a human ovum, zygote,
37	embryo, or fetus commits unlawful transfer of a human organism, a
38	Level 5 felony.
39	(d) (e) This section does not apply to the following:
40	(1) The transfer payment to or receipt by either a woman donor
41	of an ovum or a qualified third party of an amount for:
42	(A) earnings lost due to absence from employment;



1	(B) travel expenses;
2	(C) hospital expenses;
3	(D) medical expenses; and
4	(E) recovery time in an amount not to exceed four thousand
5	dollars (\$4,000);
6	concerning a treatment or procedure, including ovum
7	cryopreservation, to enhance human reproductive capability
8	through in vitro fertilization, gamete intrafallopian transfer, or
9	zygote intrafallopian transfer.
10	(2) The payment to or receipt by a qualified egg bank of an
11	amount for:
12	(A) the retrieval of a human ovum;
13	(B) the cryopreservation of a human ovum;
14	(C) the transportation of a human ovum; or
15	(D) any other aspect of performing or facilitating services
16	related to a treatment or procedure to enhance human
17	reproductive capability through in vitro fertilization.
18	(2) (3) The following types of stem cell research:
19	(A) A 1 1, , 11
	(A) Adult stem cell.
20	(B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as
20 21	(B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as the biological parent has given written consent for the use of
20 21 22	(B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as
20 21 22 23	(B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as the biological parent has given written consent for the use of
20 21 22 23 24	 (B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as the biological parent has given written consent for the use of the fetal stem cells. (3) (4) The transfer or receipt of a fetus if: (A) the fetus was diagnosed with a lethal fetal anomaly and
20 21 22 23 24 25	(B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as the biological parent has given written consent for the use of the fetal stem cells.(3) (4) The transfer or receipt of a fetus if:
20 21 22 23 24 25 26	 (B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as the biological parent has given written consent for the use of the fetal stem cells. (3) (4) The transfer or receipt of a fetus if: (A) the fetus was diagnosed with a lethal fetal anomaly and written medical documentation verifies the diagnosis; and (B) a biological parent has requested, in writing, the transfer
20 21 22 23 24 25 26 27	 (B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as the biological parent has given written consent for the use of the fetal stem cells. (3) (4) The transfer or receipt of a fetus if: (A) the fetus was diagnosed with a lethal fetal anomaly and written medical documentation verifies the diagnosis; and
20 21 22 23 24 25 26 27 28	 (B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as the biological parent has given written consent for the use of the fetal stem cells. (3) (4) The transfer or receipt of a fetus if: (A) the fetus was diagnosed with a lethal fetal anomaly and written medical documentation verifies the diagnosis; and (B) a biological parent has requested, in writing, the transfer of the fetus for purposes of an autopsy. (c) (f) Any person who recklessly, knowingly, or intentionally uses
20 21 22 23 24 25 26 27 28 29	 (B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as the biological parent has given written consent for the use of the fetal stem cells. (3) (4) The transfer or receipt of a fetus if: (A) the fetus was diagnosed with a lethal fetal anomaly and written medical documentation verifies the diagnosis; and (B) a biological parent has requested, in writing, the transfer of the fetus for purposes of an autopsy. (e) (f) Any person who recklessly, knowingly, or intentionally uses a human embryo created with an ovum provided to a qualified third
20 21 22 23 24 25 26 27 28	 (B) Fetal stem cell (as defined in IC 16-18-2-128.5), as long as the biological parent has given written consent for the use of the fetal stem cells. (3) (4) The transfer or receipt of a fetus if: (A) the fetus was diagnosed with a lethal fetal anomaly and written medical documentation verifies the diagnosis; and (B) a biological parent has requested, in writing, the transfer of the fetus for purposes of an autopsy. (c) (f) Any person who recklessly, knowingly, or intentionally uses

